文献速递类风湿关节炎

类风湿关节炎疾病控制后逐步减停TNF抑制剂与csDMARDs的随机对照TARA研究首年结果

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
PubMed 文献 · Ann Rheum Dis · 2019-04-06

TARA研究为多中心单盲随机对照试验,纳入189例已达疾病控制(DAS≤2.4且SJC≤1)且同时使用csDMARD与TNF抑制剂的RA患者,随机分为逐步减停csDMARD组(n=94)或减停TNF抑制剂组(n=95)。1年随访时两组累积复发率分别为33%(95%CI 24%–43%)与43%(95%CI 33%–53%)(p=0.17),DAS、HAQ-DI、EQ-5D无差异;减停TNF抑制剂并不优于减停csDMARDs。

要点

  • RA疾病控制后逐步减停csDMARDs或TNF抑制剂,9个月内复发率相似。
  • 1年时减停csDMARDs组复发率较低但差异无统计学意义(p=0.17)。
  • 从社会视角可优先减停TNF抑制剂以降低成本并减少长期副作用。

核心结论

  • 在RA疾病控制后,逐步减停TNF抑制剂并不优于逐步减停csDMARDs。
  • 1年时减停csDMARDs组复发率较减停TNF抑制剂组低10%,但差异无统计学意义。

研究设计与样本

  • 多中心单盲(研究护士盲)随机对照试验,纳入同时使用csDMARD和TNF抑制剂且疾病控制(DAS≤2.4且SJC≤1)的RA患者。
  • 189例患者随机分为逐步减停csDMARDs组(n=94)或减停TNF抑制剂组(n=95)。
  • 减停方式为在疾病仍控制时依次将剂量减半、减至四分之一、之后停药。

主要发现

  • csDMARD减停组与抗TNF减停组的累积复发率分别为33%(95%CI 24%–43%)和43%(95%CI 33%–53%)(p=0.17)。
  • 1年时及随时间推移,两组平均DAS、HAQ-DI和EQ-5D无差异。

关键数值与推荐

  • 疾病控制定义为DAS≤2.4且肿胀关节计数(SJC)≤1。
  • 复发定义为DAS>2.4和/或SJC>1。

临床怎么用

  • 对于同时使用csDMARD和TNF抑制剂且已达疾病控制的RA患者,可考虑逐步减停TNF抑制剂。
  • 从社会视角,优先减停TNF抑制剂可能降低成本并减少长期副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study is to evaluate the effectiveness of two tapering strategies after achieving controlled disease in patients with rheumatoid arthritis (RA), during 1 year of follow-up. METHODS: In this multicentre single-blinded (research nurses) randomised controlled trial, patients with RA were included who achieved controlled disease, defined as a Disease Activity Score (DAS) ≤ 2.4 and a Swollen Joint Count (SJC) ≤ 1, treated with both a conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and a TNF inhibitor. Eligible patients were randomised into gradual tapering csDMARDs or TNF inhibitors. Medication was tapered if the RA was still under control, by cutting the dosage into half, a quarter and thereafter it was stopped. Primary outcome was proportion of patients with a disease flare, defined as DAS > 2.4 and/or SJC > 1. Secondary outcomes were DAS, European Quality of Life-5 Dimensions (EQ5D) and functional ability (Health Assessment Questionnaire Disability Index [HAQ-DI]) after 1 year and over time. RESULTS: A total of 189 patients were randomly assigned to tapering csDMARDs (n = 94) or tapering anti-TNF (n = 95). The cumulative flare rates in the csDMARD and anti-TNF tapering group were, respectively, 33 % (95% CI,24% to 43 %) and 43 % (95% CI, 33% to 53 % (p = 0.17). Mean DAS, HAQ-DI and EQ-5D did not differ between tapering groups after 1 year and over time. CONCLUSION: Up to 9 months, flare rates of tapering csDMARDs or TNF inhibitors were similar. After 1 year, a non-significant difference was found of 10 % favouring csDMARD tapering. Tapering TNF inhibitors was, therefore, not superior to tapering csDMARDs. From a societal perspective, it would be sensible to taper the TNF inhibitor first, because of possible cost reductions and less long-term side effects. TRIAL REGISTRATION NUMBER: NTR2754.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis. 2019. PMID: 30954969. doi:10.1136/annrheumdis-2018-214970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。